|
R & D synthetic chemistry department of Cadila Pharmaceuticals
has a major objective of developing processes of synthesis for
various bulk actives and to commercialize the technology up
to production scale. We keep in mind the high quality standards
required by international pharmaceutical companies and we respect
the Intellectual Property Rights of other organizations. This
lead us to develop patentable, non-infringing processes that
are commercially viable and cost effective so as to be globally
competent.
To meet this objective we have a full-fledged world class R
& D unit with ultra modern facilities. Our multi - centric
research facilities are situated at Dholka, Ankleshwar and at
Bangalore.
We have, well equipped Analytical Research Laboratory with all
necessary facilities like HPLC, preparative HPLC, HPTLC, FT-
IR, DSC, GC, GC Head Space analyzer, LC-MS/MS, Karl Fischer,
Polarimeter, UV spectrophotometer, high precision digital melting
point apparatus with monitor, Malvern particle size analyzer
etc.
We have an excellent and
well-equipped library having international Journals apart from
various technical books and monographs to augment research activity.
Our Informatics department is equipped with online search facilities
like STN, Scifinder etc.
We have 60 scientists in our R & D Department [Organic Synthesis
Division] and 20 analytical scientists [Analytical Research
Division] with Ph.Ds, M.Tech, B. Tech, M.Sc and M. Pharm degrees.
We develop multi-step total synthesis of molecule in our chemistry
lab up to about 500 gm scale which undergoes optimization and
yield improvement till all quality parameters are fixed to result
in a validated lab process. This then goes to pilot scale in
the same building on a reactor scale from 3 kg scale up to 10
kg scale where all engineering process parameters are fine-tuned
and our skilled process engineers establish ruggedness of the
technology.
After pilot scale experiments are established, the process is
then ready for commercial production. We give maximum attention
to produce high quality bulk actives free from related impurities,
so as to qualify acceptance criteria laid by ANDA and other
stringent regulatory norms.
We are also conscious and have the expertise
to provide therapeutically acceptable, stable polymorph for
different bulk actives.
|
